Medical Director, Radiopharmaceutical Imaging (RPI) at Bristol-Myers Squibb

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

MD or equivalent
At least 5 years of pharmaceutical, biotech experience or academic clinical experience in oncology diagnostic development, or 3 years (incomplete in description)
Willing to travel approximately 30% of the time
Willingness to involve evening and weekend work

Responsibilities

Interact with clinical investigators and thought leaders to design a diagnostic imaging strategic plan for nominated candidates
Lead internal project teams, and partner with investigators and CROs to design and implement clinical studies of radiopharmaceutical imaging agents
Contribute to writing of protocols, investigator brochures, clinical study reports, and review of other clinical trial and regulatory documents
Conduct investigator meetings and lead site qualification and initiation visits with clinical trial investigators
Execute and deploy drug development strategic plans, develop contingency plans, provide technical and strategic advice, and meet milestones and budgets
Translate findings from research and nonclinical studies into diagnostic imaging development opportunities
Oversee Data Review and Independent Data Monitoring Committees as applicable
Conduct clinical trials using ethical guidelines relevant to the pharmaceutical industry, and ensure compliance with these external guidelines
Establish and maintain positive relationships with clinical trial investigators and thought leaders
Serve as clinical lead for regulatory interactions, including preparation of briefing documents and attendance and presentation at health authority meetings
Work closely with commercial and medical affairs organization to develop and execute on a diagnostic imaging program for RayzeBio portfolio in radiopharmaceutical imaging
Support IND preparation, regulatory authority interactions, design, and execution of Phase 0 to Phase 3 clinical trials, and medical monitoring

Skills

Radiopharmaceutical Imaging

Clinical Trials

IND Preparation

Regulatory Interactions

Medical Monitoring

Prostate Cancer

Hepatocellular Cancer

Neuroendocrine Tumors

Diagnostic Imaging

Phase 0-3 Trials

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free